Investigational Drug Information for Anisodamine
✉ Email this page to a colleague
What is the drug development status for Anisodamine?
Anisodamine is an investigational drug.
There have been 6 clinical trials for Anisodamine.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Shock, Shock, Septic, and Critical Illness. The leading clinical trial sponsors are Alphacait, LLC, Haining Health-Coming Biotech Co., Ltd., and Chen Ying.
Summary for Anisodamine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 155 |
| WIPO Patent Applications | 71 |
| Japanese Patent Applications | 18 |
| Clinical Trial Progress | Phase 3 (2013-08-01) |
| Vendors | 84 |
Recent Clinical Trials for Anisodamine
| Title | Sponsor | Phase |
|---|---|---|
| Effectiveness of Anisodamine Hydrobromide Combined With Heparin for the Treatment of Critically Ill Patients With Septic Shock | Chen Ying | N/A |
| FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | Sun Yat-sen University | Phase 2 |
| Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor | Alphacait, LLC | Phase 2 |
Clinical Trial Summary for Anisodamine
Top disease conditions for Anisodamine
Top clinical trial sponsors for Anisodamine
US Patents for Anisodamine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
